Where does stocks-llm's data on ALKS come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like ALKS →

ALKERMES (ALKS)

Health Care · Specialty neuroscience and psychiatry pharmaceuticals · NASDAQ

Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance use disorders with proprietary long-acting injectable and extended-release technologies.

View SEC filings Website Yahoo Finance Find companies like ALKS → Ask about ALKS →

What ALKERMES does

Alkermes plc is a global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. The company markets branded products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy, alongside a clinical pipeline of candidates in neurological and neuropsychiatric disorders including late-stage programs in narcolepsy and idiopathic hypersomnia.

Themes: ["Neuropsychiatry / antipsychotics","Substance use disorders (alcohol, opioid dependence)","Narcolepsy and sleep disorders","Long-acting injectable therapies","ADHD medications (early-stage pipeline)","Rare neurological disorders"]

Fundamentals

Price$53.78 as of 2026-07-09 close
Market cap$9.0B as of 2026-07-10
1-year return+79.4% as of 2026-07-09 close
P/E59.25 as of 2026-07-10
Net margin+9.8% as of 2026-07-10
Gross margin+86.6% as of 2026-07-10
ROE+8.8% as of 2026-07-10
Debt / equity0.86 as of 2026-07-10
Revenue growth (YoY)+3.2% as of 2026-07-10
Revenue CAGR (3y)+9.9% SEC XBRL
Beta0.26 as of 2026-07-10

Ask why ALKS looks like this →

Key risks (from latest filing)

["Heavy dependence on product acceptance and physician prescribing patterns; adverse publicity regarding products or similar drug classes could reduce demand and reimbursement","Regulatory risks including FDA oversight, REMS program compliance, DEA scheduling, and potential generic competition or product label changes that restrict use","Reimbursement and pricing pressure from government payers (Medicare, Medicaid), managed care organizations, and participation in mandatory discount programs (MDRP, 340B) that reduce net revenues"]

See ALKS's biggest risks from its latest 10-Q →

Competitors & peers

Johnson & Johnson (JNJ)
Eli Lilly (LLY)
Bristol Myers Squibb (BMY)
Otsuka Pharmaceutical
Lundbeck
Naurex (Celgene/BMS)
Revance Therapeutics

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.